[{"orgOrder":0,"company":"IRICoR","sponsor":"ExCellThera","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"ECT-001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"IRICoR","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IRICoR \/ IRICoR","highestDevelopmentStatusID":"4","companyTruncated":"IRICoR \/ IRICoR"},{"orgOrder":0,"company":"IRICoR","sponsor":"Universite de Montreal","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"IRICoR","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IRICoR \/ Universite de Montreal","highestDevelopmentStatusID":"3","companyTruncated":"IRICoR \/ Universite de Montreal"}]

Find Clinical Drug Pipeline Developments & Deals by IRICoR

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Cell Therapy
                          Not Confirmed
                          Cell Therapy
                          Not Confirmed

                          Details : The collaboration builds on research from the team of Dr. Daniel Levesque at UdeM, and focuses on the design of highly selective modulators of the Nur77/RXR nuclear receptor complex, a promising new pharmacological target for movement disorders.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          October 03, 2021

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Neurology

                          Highest Development Status : Discovery Platform

                          Sponsor : Universite de Montreal

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          Cell Therapy
                          Not Confirmed
                          Cell Therapy
                          Not Confirmed

                          Details : IRICoR's investment enabled ExCellThera to secure the co-funding required in connection with the grant awarded to it from the California Institute for Regenerative Medicine for a Phase 1 clinical trial using its ECT-001, for the treatment of severe sickl...

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          July 08, 2020

                          Lead Product(s) : ECT-001

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Preclinical

                          Recipient : ExCellThera

                          Deal Size : Undisclosed

                          Deal Type : Funding

                          blank